Finally, the VEGF Liver 100 trial evaluated the anti-PD-L1 avelumab in combination with axitinib (VEGF receptor 1/2/3 inhibitor) in treatment-naïve advanced HCC patients [50]. The gene discussed is CD274; the disease is hepatocellular carcinoma.